Canexis Pharma AG – New Construction of a GMP Production Facility
The start‑up Canexis Pharma AG specializes in the processing of medical cannabis. As general planner, IE Life Science delivered a state‑of‑the‑art production facility in Schlattingen that combines complex extraction processes with strict GMP requirements in a functional new building.
From Start-up to GMP-Certified Production
Project
Planning and construction of a new production facility for processing cannabis flowers into high‑quality bulk products such as extracts and isolates, fully compliant with the strictest GMP requirements.
Client
Canexis Pharma AG
Key Data
Working Together for Project Success
Services provided by IE Group
- Flexible, expandable zoning concept based on forward‑looking planning
- Consistent separation of material and personnel flows for GMP‑compliant production
- Timely handover after only two years of planning and construction
- Precisely optimized cleanroom areas with an optimal cost‑benefit ratio
- Reliable compliance with quality, cost and schedule guarantees
- Long‑term growth potential through a flexibly expandable building concept
Challenges & Solutions
Highest GMP Requirements With a Strictly Limited Start‑Up Budget
Safe Handling of Flammable Solvents in a GMP Environment
Future‑Proof Infrastructure for a Growing Market Segment
The Project in Detail
Legal hemp is already processed into more than 50,000 products worldwide, and Switzerland is among the first European markets to permit the regulated medical use of THC‑containing cannabis. Canexis Pharma AG recognized this development at an early stage and positioned itself as a specialist in the processing of medical cannabis.For the construction of a modern GMP‑compliant production facility for processing cannabis flowers, Canexis Pharma AG selected the industrial construction specialists at IE Life Science. The decision was driven not only by IE’s proven pharmaceutical and construction expertise, but also by its ability to provide binding guarantees for cost, schedule and quality.
The Challenge
The processing of medical cannabis into pharmaceutical ingredients is subject to extremely strict regulatory requirements. As a start‑up, Canexis Pharma needed to establish an infrastructure that met current GMP standards while remaining scalable for future growth. Key challenges included the safe handling of flammable solvents used in extraction processes (explosion protection), strict compliance with hygiene and safety zoning, and adherence to Swissmedic requirements as well as narcotics legislation.
Key Success Factors
IE Life Science impressed with its fully integrated planning approach. From the initial layout studies through to cleanroom qualification, all processes were consistently aligned with GMP requirements. The design‑to‑cost principle ensured budget compliance without compromising quality. Particularly valuable for the young company was the assumption of full general planning responsibility, the reduction of interfaces, the timely commissioning of the facility, and the successful achievement of GMP certification – providing a solid foundation for future growth.
Deepen Your Knowledge
Discover further details in our Project Insight.